Kinapse solution to improve efficiency and enhance overall sponsor
experience with Veeva's next-generation submission application
PHILADELPHIA--(BUSINESS WIRE)--
DIA 2016 Annual Meeting – Today at the Drug Information
Association’s (DIA) Annual Meeting, Veeva
Systems (NYSE: VEEV) and Kinapse
Ltd., a leading provider of life sciences advisory and operational
services, announced that Kinapse has selected Veeva
Vault Submissions to power its new regulatory operational services.
Veeva Vault Submissions provides Kinapse a modern cloud application for
authoring and managing regulatory submissions content. Kinapse will now
offer sponsors the option to produce regulatory deliverables on Vault
Submissions and leverage Kinapse’s new efficient processes that have
been optimized on Veeva’s cloud platform.
“Service providers play an increasing role in regulatory operations
today,” said Katrin Spaepen, director of Vault RIM Strategy at Veeva
Systems. “Veeva Vault Submissions will provide Kinapse customers a
shared authoritative source for submissions content. Combined with
Kinapse’s services, sponsors can achieve global accessibility and
real-time visibility into their regulatory submissions processes.”
Today there are two ways sponsors work with regulatory submissions
service providers. Sponsors have service providers access their
on-premise systems remotely, slowing performance and limiting innovation
by constraining the service provider to follow the sponsor’s model of
operation. Alternatively, sponsors author, review, and approve
submission documents within their own systems then manually transmit
documents to submission partners. This makes document changes difficult
to track, creating inefficiencies and increasing risk.
“Veeva Vault Submissions changes how sponsors and their partners
collaborate by providing fast, direct access to manage content and
data,” said Marc Gabriel, client partner at Kinapse. “Veeva Vault
ensures submissions are managed with greater quality, efficiency, and
control by allowing the sponsor and service provider to access their
documents and data through the cloud and view status in real-time.”
Kinapse is coupling Vault Submissions with a new set of streamlined
regulatory processes that take advantage of Veeva’s advanced
capabilities for regulated document management. Kinapse rigorously
tested the platform’s key functions, including the segmentation of
client data. The Kinapse regulatory team is trained and ready to deliver
submissions on the Vault platform.
“There is significant interest around Veeva’s unique cloud applications
for regulatory information management (RIM),” said Aileen Fisher, vice
president of Regulatory Affairs and Pharmacovigilance Services for
Kinapse. “With Veeva Vault Submissions, we expect our customers to
benefit from greater access, visibility, and control over their
submissions information and, ultimately, speed their time to submission.”
Kinapse provides the biopharmaceutical industry with services across the
product lifecycle, including submission management, strategy,
publishing, CMC authoring, labeling, intelligence, safety reports, and
full pre- and post-submission support.
Kinapse plans to add other Veeva
Vault RIM applications to their service offerings, including Veeva
Vault Registrations and Veeva
Vault Submissions Archive.
Additional Information
For more on Veeva Vault Submissions, visit: veeva.com/VaultSubmissions
Stay
updated on the latest Veeva news on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
For
more on Kinapse regulatory services, visit: kinapse.com/our-expertise/our-services/regulatory-affairs/
Stay
updated on the latest Kinapse news on LinkedIn: linkedin.com/company/kinapse
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 400 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
About Kinapse
Kinapse provides expert advisory, capability building and operational
services to the world’s leading life sciences organizations, their
customers, suppliers and regulators. Their clients include many of the
world’s leading pharmaceutical companies, their customers, suppliers and
regulators. Kinapse uses a novel operating and delivery model that
allows them to bring together the very best people in virtual teams, in
a wide range of R&D domains, committed to the success of our clients.
Headquartered in London, Kinapse currently employs over 600 people in
the U.K., U.S. and India. For more information, please visit http://www.kinapse.com/.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in the company’s filing on Form
10-Q for the period ended April 30, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160627005239/en/
Source: Veeva Systems Inc.